Education
About Us
Working with TipRanks
Follow Us
SkinBioTherapeutics PLC (GB:SBTX)
LSE:SBTX
SBTX Stock Chart & Stats
13.25p
-0.88p(-5.43%)
At close: 4:00 PM EST
13.25p
-0.88p(-5.43%)
Day’s Range― - ―
52-Week Range5.50p - 27.50p
Previous CloseN/A
Volume282.34K
Average Volume (3M)673.17K
Market Cap
£16.46M
Enterprise Value11.76M
Total Cash (Recent Filing)£4.78M
Total Debt (Recent Filing)£993.47K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Mar 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding259,168,670
10 Day Avg. Volume831,404
30 Day Avg. Volume673,172
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)4.06
Price to Sales (P/S)8.25
P/FCF Ratio-29.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line expansion (+73% reported) signals growing product acceptance and distribution traction. Over 2–6 months this revenue momentum supports reinvestment in R&D, marketing, and clinical work, increasing odds of scaling toward profitable unit economics if margins are controlled.
Conservative LeverageA low debt profile and healthy equity ratio provide financing flexibility and resilience. This reduces short-term refinancing pressure, allowing the company to prioritize R&D, regulatory work, or partnership deals without urgent debt-servicing constraints over the coming months.
Proprietary Microbiome FocusA differentiated, science-backed microbiome platform and topical formulations create durable competitive advantage in an expanding skincare niche. Clinical validation and IP-backed ingredients enhance licensing and co-branding prospects, supporting recurring revenue sources and market differentiation.
Bears Say
Persistent UnprofitabilityOngoing negative net income and EBIT margins indicate core operations do not yet generate profits. Without sustained margin improvement or structural cost reduction, profitability may remain elusive, constraining retained earnings and long-term value creation for shareholders.
Negative Cash FlowThe company reports negative operating and free cash flows, signaling cash burn from operations. This weak cash generation threatens runway and may force external financing, licensing concessions, or slower commercial expansion, impacting strategic flexibility over several months.
Limited Operational ScaleA very small team constrains capacity for large-scale commercialization, regulatory submissions, and multi-partner rollouts. Scaling manufacturing, marketing, and clinical programs typically requires hiring or partnerships, which can delay execution and increase dependency on external collaborators.
SkinBioTherapeutics News
SBTX FAQ
What was SkinBioTherapeutics PLC’s price range in the past 12 months?
SkinBioTherapeutics PLC lowest share price was 5.50p and its highest was 27.50p in the past 12 months.
What is SkinBioTherapeutics PLC’s market cap?
SkinBioTherapeutics PLC’s market cap is £16.46M.
When is SkinBioTherapeutics PLC’s upcoming earnings report date?
SkinBioTherapeutics PLC’s upcoming earnings report date is Mar 31, 2026 which is in 40 days.
How were SkinBioTherapeutics PLC’s earnings last quarter?
SkinBioTherapeutics PLC released its earnings results on Dec 05, 2025. The company reported 0.001p earnings per share for the quarter, beating the consensus estimate of N/A by 0.001p.
Is SkinBioTherapeutics PLC overvalued?
According to Wall Street analysts SkinBioTherapeutics PLC’s price is currently Overvalued.
Does SkinBioTherapeutics PLC pay dividends?
SkinBioTherapeutics PLC does not currently pay dividends.
What is SkinBioTherapeutics PLC’s EPS estimate?
SkinBioTherapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SkinBioTherapeutics PLC have?
SkinBioTherapeutics PLC has 259,168,670 shares outstanding.
What happened to SkinBioTherapeutics PLC’s price movement after its last earnings report?
SkinBioTherapeutics PLC reported an EPS of 0.001p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.023%.
Which hedge fund is a major shareholder of SkinBioTherapeutics PLC?
Currently, no hedge funds are holding shares in GB:SBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SkinBioTherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.00%
12-Months-Change
Fundamentals
Return on Equity
-11.24%
Trailing 12-Months
Asset Growth
73.26%
Trailing 12-Months
Company Description
SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.
Technical Analysis
ImmuPharma
―
OptiBiotix Health
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Ondine Biomedical, Inc.
―